 | | Vol. 12.44 – 29 November, 2023 |
| |
|
|
| Researchers reported that high expression of inhibitor of differentiation 1 (ID1) in tumor-associated macrophages correlated with poor outcomes in patients with colorectal cancer.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists revealed the contributions of NRCAM to liver CSC function and hepatocellular carcinoma metastasis, and further explored its mechanism in detail.
[Journal Of Experimental & Clinical Cancer Research] |
|
|
|
| The authors elucidated the function of the nuclear receptor subfamily 5, group A, member 2 (NR5A2) in the context of pancreatic CSCs.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Scientists elucidated the role of Mitotic arrest deficient 2 like 2 (MAD2L2) in maintaining glioblastoma stemness and promoting malignant behaviors through the regulation of c-MYC.
[Journal of Translational Medicine] |
|
|
|
| Researchers explored the function of regulator of chromosome condensation 2 (RCC2) on prostate cancer (PCa) development. They found that RCC2 promoted PCa development through Hh/Gli1 signaling pathway via regulating epithelial-mesenchymal transition and CSCs.
[Biology Direct] |
|
|
|
| Investigators revealed that TET1 could regulate the phenotype of CSCs via OCT4. Additionally, it could control the cell cycle by increasing CDK1 and CCNB1 levels.
[Biochemical Pharmacology] |
|
|
|
| RNA sequencing found that 1-benzylimidazole held a preferable correlation with breast cancer and suppressed the expression of CSC makers.
[Environmental Toxicology] |
|
|
|
| Investigators evaluated whether leukemia stem cells was influenced by mitochondrial inhibition. They demonstrated that the inhibition of mitochondrial activity by tigecycline affects CSCs in comparison with other cells.
[Cell Biochemistry And Function] |
|
|
|
| Transcription factor MITF inhibited transcription of CPT1B to regulate fatty acid β-oxidation, thereby suppressing stemness in lung adenocarcinoma cells.
[Pharmacology] |
|
|
|
|
| Scientists provide an update on the current landscape of nanobased precision targeting approaches against CSCs. They elucidate the nuanced application of organic, inorganic, and bioinspired nanomaterials across a spectrum of therapeutic paradigms, encompassing targeted therapy, and more.
[ACS Nano] |
|
|
|
| The authors summarize the mechanisms of redox regulation in CSCs, with a focus on therapy resistance, its various pathways and microRNA regulation, and the potential therapeutic implications of manipulating the reactive oxygen species levels to eradicate CSCs.
[Journal of Cellular Biochemistry] |
|
|
|
|
| Researchers at the Montefiore Einstein Comprehensive Cancer Center were awarded a $2.6 million grant from the US FDA to conduct an innovative Phase I clinical trial of a new drug for patients with relapsed and treatment-resistant forms of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
[Albert Einstein College of Medicine] |
|
|
|
|
| January 22 – 25, 2024
Santa Fe, New Mexico, United States |
|
|
|
|
|
| | Westlake University – Zhejiang, China |
|
|
|
| | Swammerdam Institute for Life Sciences – Amsterdam, Netherlands |
|
|
|
| | BC Cancer – Vancouver, British Columbia, Canada |
|
|
|
| | Babraham Institute – Cambridge, England, United Kingdom |
|
|
|
| | University of Oxford – Oxford, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
